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OBJECTIVE: Injection drug users comprise more than
35% of new HIV cases, while an estimated 69.1% of
patients currently enrolled in methadone maintenance
programs (MMT) receive sub-optimal dosages (<80mg/
day). Buprenorphine (BPN) has been suggested as an
alternative to methadone due to less adverse effects and
lower abuse potential. However, BPN has not consistently
outperformed optimal dose MMT. The objective is to
compare the cost-utility of selective BPN substitution into
current practice MMT, with emphasis on its role in HIV
infection. We also explore the cost-utility of increasing
minimum methadone dosage from current practice.
METHODS: We employed a dynamic epidemic (Markov)
model to measure the effects of substituting BPN for 
sub-optimal methadone dosing (SubMT) (<60mg or 
<80mg/d) on health care costs and quality-adjusted life-
years (QALYs) of intravenous heroin users. Analyses were
performed with HIV prevalence of 5% or 40% within the
population, considering a cost of $5 per day for BPN
therapy. Figures are calculated using a 100-year time
horizon, calculating present discounted values for both
health care costs and QALYs.
RESULTS: Substitution of BPN for SubMT <60mg, and
<80mg, per day result in a cost per additional QALY of
$5,580–$14,790, and $18,957–$59,431, respectively.
Increasing the minimum dose of therapy to 80mg per day
dominates all alternative treatment regimes, though
increasing minimum doses to 60mg is also superior to
current practice. BPN is dominant over increasing
minimum methadone doses to 60mg, but not to 80mg,
if BPN increases quality of life by 1% over MMT through
reduced adverse effects.
CONCLUSIONS: Selective substitution of BPN for
methadone is cost-effective for daily methadone doses
below 60mg, and may be cost-effective for all doses
below 80mg depending on side-effect proﬁle and HIV
prevalence. BPN provides a useful additional treatment
approach, though BPN appears less cost-effective than
optimal-dose methadone therapy.
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INITIAL ANTIMICROBIAL THERAPY AND
OUTCOMES IN PATIENTS HOSPITALIZED WITH
COMMUNITY-ACQUIRED PNEUMONIA (CAP)
Onesirosan PT, Gutierrez B, Gaylord-Miles B, Hatch V
Premier, Inc, Charlotte, NC, USA
OBJECTIVES: Wide variations in antimicrobial manage-
ment of CAP have been reported despite the existence of
guidelines. The objective of this analysis was to assess the
association between initial antimicrobial therapy and out-
comes (therapy duration, total antimicrobial cost, length
of stay and total hospital cost) in two subpopulations of
hospitalized adults with ICD-9 codes for CAP: ICU and
non-ICU.
METHODS: The antimicrobial regimen received within
the ﬁrst 72 hours was determined for CAP patients from
188 facilities between January and December 2000.
RESULTS: Among ICU patients, initial therapy with a
ﬂuoroquinolone alone was associated with the best out-
comes, followed by a ﬂuoroquinolone plus a 3rd genera-
tion cephalosporin, a macrolide plus a 3rd generation
cephalosporin, a beta-lactam/beta-lactamase inhibitor
alone, and other regimens. This ranking was consistent
across all levels of pneumonia severity. Of the 12 initial
therapy regimens identiﬁed among non-ICU patients, a
macrolide alone gave the best outcome, followed by a 
ﬂuoroquinolone alone, a 2nd generation cephalosporin
plus a macrolide, and a 2nd generation cephalosporin
alone. The worst outcomes were associated with a ﬂuo-
roquinolone plus a penicillin, followed by a ﬂuoro-
quinolone plus other cephalosporin. This ranking was
also consistent across all levels of pneumonia severity.
Fifty-nine percent of the initial therapy regimens for non-
ICU patients were consistent with the Infectious Diseases
Society of America’s guidelines (1998) compared with
only 22% for ICU patients.
CONCLUSIONS: Initial therapy with a ﬂuoroquinolone
alone, a regimen inconsistent with the IDSA guidelines,
gave the best outcomes for CAP patients in the ICU while
a macrolide alone (guideline-consistent) was associated
with the best outcomes for non-ICU patients.
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COSTS OF TREATMENT FOR AMBULATORY
LOWER RESPIRATORY TRACT INFECTION IN
QUEBEC SENIORS
Kennedy WA, Laurier C, Paré M, Philibert L
University of Montreal, Montreal, QC, Canada
OBJECTIVES: Evaluate costs of ambulatory treatment of
lower respiratory tract infection (LRTI) in seniors.
METHODS: Using claims data from Quebec public
provincial health programs for physician services and 
prescriptions dispensed, we drew a sample of seniors
diagnosed with LRTI in an ambulatory setting subse-
quently receiving an antibiotic from a community phar-
macy. Failure of antibiotic was deﬁned as receipt of a
second antibiotic or inpatient physician visit with LRTI
diagnosis within a 15-day window following antibiotic
receipt. Costs of treatment (CDN$) were those associated
with treatment episode and included medical visits,
antibiotics, and hospitalisations associated with LRTI
diagnosis. Treatment episode started with the initial visit
and terminated 15 days after end of recorded duration of
antibiotic received, extended by treatment duration (plus
15 days) of any additional antibiotics received during this
